GAF Healthcare
Specialty Overview

Best Hospitals for Hematopoietic Stem Cell Transplantation (HSCT) in Chennai, India

8 bone marrow transplant hospitals in our India network are listed in Chennai, accredited by JCI, NABH, NABL, with 4,035 beds combined.

8
Hospitals Listed
1
City
4.5
Avg. Rating
3
Accreditation Types
The Short Answer

This page lists the bone marrow transplant hospitals in our directory offering Hematopoietic Stem Cell Transplantation (HSCT) in Chennai, India, including Apollo Hospitals, Greams Road, Gleneagles Global Hospital, Dr. Rela Institute and Medical Centre, SIMS Hospital and others. Each listing links through to the hospital's full profile page.

Including:🇮🇳 Apollo Hospitals, Greams Road🇮🇳 Gleneagles Global Hospital🇮🇳 Dr. Rela Institute and Medical Centre

Ask us about hematopoietic stem cell transplantation (hsct) in Chennai, India

Share a few details and our care coordination team will get back to you with next steps.

Compare 8 accredited hospitals for Bone Marrow Transplant in Chennai, India

Apollo Hospitals, Greams Road Featured
Starting from$18,000

🇮🇳 Apollo Hospitals, Greams Road

Chennai, India 4.7 (125 reviews) 560 beds
Why consider this hospital?
4.7/5 rating from 125 reviewsAccredited by JCI, NABH560 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyMedical OncologyBreast SurgerySpine SurgeryBariatric Surgery
Accredited by JCI, NABH

Patients considering hematopoietic stem cell transplantation (hsct) can be cared for by Apollo Hospitals, Greams Road's care team in Chennai, India, from initial consultation through recovery. Apollo Hospitals, Greams Road, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing hematopoietic stem cell transplantation (hsct).

4.7/5
Rating
1983
Established
560
Beds
Chennai, India
Location
Enquire NowView Profile
Gleneagles Global Hospital
Starting from$18,000

🇮🇳 Gleneagles Global Hospital

Chennai, India 4.7 (112 reviews) 1,000 beds
Why consider this hospital?
4.7/5 rating from 112 reviewsAccredited by NABH, JCI1,000 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyMedical OncologyBreast SurgerySpine SurgeryBariatric Surgery
Accredited by NABH, JCI

Patients considering hematopoietic stem cell transplantation (hsct) can be cared for by Gleneagles Global Hospital's care team in Chennai, India, from initial consultation through recovery. Gleneagles Global Hospital, accredited by NABH, JCI, follows recognised patient-safety and quality-of-care standards when performing hematopoietic stem cell transplantation (hsct).

4.7/5
Rating
1999
Established
1,000
Beds
Chennai, India
Location
Enquire NowView Profile
Dr. Rela Institute and Medical Centre
Starting from$18,000

🇮🇳 Dr. Rela Institute and Medical Centre

Chennai, India 4.7 (108 reviews) 450 beds
Why consider this hospital?
4.7/5 rating from 108 reviewsAccredited by NABH, NABL450 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyMedical OncologyBreast SurgerySpine SurgeryBariatric Surgery
Accredited by NABH, NABL

Patients considering hematopoietic stem cell transplantation (hsct) can be cared for by Dr. Rela Institute and Medical Centre's care team in Chennai, India, from initial consultation through recovery. Dr. Rela Institute and Medical Centre, accredited by NABH, NABL, follows recognised patient-safety and quality-of-care standards when performing hematopoietic stem cell transplantation (hsct).

4.7/5
Rating
2018
Established
450
Beds
Chennai, India
Location
Enquire NowView Profile
SIMS Hospital
Starting from$18,000

🇮🇳 SIMS Hospital

Chennai, India 4.6 (20 reviews) 345 beds
Why consider this hospital?
4.6/5 rating from 20 reviewsAccredited by NABH, JCI345 beds
Specialties & Accreditation
Cardiac SurgeryNeurosciencesTransplantOrthopedicsGastroenterology
Accredited by NABH, JCI

Patients considering hematopoietic stem cell transplantation (hsct) can be cared for by SIMS Hospital's care team in Chennai, India, from initial consultation through recovery. SIMS Hospital, accredited by NABH, JCI, follows recognised patient-safety and quality-of-care standards when performing hematopoietic stem cell transplantation (hsct).

4.6/5
Rating
1970
Established
345
Beds
Chennai, India
Location
Enquire NowView Profile
Sankara Nethralaya
Starting from$18,000

🇮🇳 Sankara Nethralaya

Nungambakkam, Chennai, India 4.4 (220 reviews) 200 beds
Why consider this hospital?
4.4/5 rating from 220 reviewsAccredited by NABH, NABL200 beds
Specialties & Accreditation
OphthalmologyRetina SurgeryCornea TransplantGlaucomaPediatric Ophthalmology
Accredited by NABH, NABL

Patients considering hematopoietic stem cell transplantation (hsct) can be cared for by Sankara Nethralaya's care team in Nungambakkam, Chennai, India, from initial consultation through recovery. Sankara Nethralaya, accredited by NABH, NABL, follows recognised patient-safety and quality-of-care standards when performing hematopoietic stem cell transplantation (hsct).

4.4/5
Rating
1978
Established
200
Beds
Nungambakkam, Chennai, India
Location
Enquire NowView Profile
Apollo First Med Hospitals, Kilpauk
Starting from$18,000

🇮🇳 Apollo First Med Hospitals, Kilpauk

Kilpauk, Chennai, India 4.4 (76 reviews) 80 beds
Why consider this hospital?
4.4/5 rating from 76 reviewsAccredited by NABH, JCI80 beds
Specialties & Accreditation
Cardiac SciencesOrthopedicsNeurologyOncologyGastroenterology
Accredited by NABH, JCI

Patients considering hematopoietic stem cell transplantation (hsct) can be cared for by Apollo First Med Hospitals, Kilpauk's care team in Kilpauk, Chennai, India, from initial consultation through recovery. Apollo First Med Hospitals, Kilpauk, accredited by NABH, JCI, follows recognised patient-safety and quality-of-care standards when performing hematopoietic stem cell transplantation (hsct).

4.4/5
Rating
2002
Established
80
Beds
Kilpauk, Chennai, India
Location
Enquire NowView Profile
MIOT International
Starting from$18,000

🇮🇳 MIOT International

Manapakkam, Chennai, India 4.4 (200 reviews) 1,000 beds
Why consider this hospital?
4.4/5 rating from 200 reviewsAccredited by NABH, NABL, JCI1,000 beds
Specialties & Accreditation
OrthopedicsCardiac SurgeryNeurosciencesTransplantOncology
Accredited by NABH, NABL, JCI

Patients considering hematopoietic stem cell transplantation (hsct) can be cared for by MIOT International's care team in Manapakkam, Chennai, India, from initial consultation through recovery. MIOT International, accredited by NABH, NABL, JCI, follows recognised patient-safety and quality-of-care standards when performing hematopoietic stem cell transplantation (hsct).

4.4/5
Rating
1999
Established
1,000
Beds
Manapakkam, Chennai, India
Location
Enquire NowView Profile
MGM Healthcare
Starting from$18,000

🇮🇳 MGM Healthcare

Chennai, India 3.7 (34 reviews) 400 beds
Why consider this hospital?
3.7/5 rating from 34 reviewsAccredited by NABH, JCI400 beds
Specialties & Accreditation
Cardiac SurgeryNeurosciencesTransplantCancer CareOrthopedics
Accredited by NABH, JCI

Patients considering hematopoietic stem cell transplantation (hsct) can be cared for by MGM Healthcare's care team in Chennai, India, from initial consultation through recovery. MGM Healthcare, accredited by NABH, JCI, follows recognised patient-safety and quality-of-care standards when performing hematopoietic stem cell transplantation (hsct).

3.7/5
Rating
1970
Established
400
Beds
Chennai, India
Location
Enquire NowView Profile
Our Methodology

How we selected these hospitals

A hospital appears on this page when Bone Marrow Transplant is among its listed specialties and it is located in Chennai, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.

What To Look For

How to Select the Best Hospital for Hematopoietic Stem Cell Transplantation (HSCT) in Chennai, India?

Choosing the right hospital for hematopoietic stem cell transplantation (hsct) is one of the most important decisions in your treatment journey. A few factors are worth weighing before you decide:

International Accreditation

Look for a hospital with international accreditation such as JCI or NABH — see the accreditation badges shown for each hospital below.

Specialization

Check that the hospital's listed specialties actually include bone marrow transplant rather than only general care.

Capacity and Track Record

Bed count and year established (shown below for each hospital) are a reasonable proxy for scale and operating experience.

Transparent Costs

Ask for an itemised, all-inclusive estimate — hospital charges, room category and stay — before you travel. Our cost calculator (linked below) gives a starting estimate.

Clinical Overview

Understanding Hematopoietic Stem Cell Transplantation (HSCT)

Haematopoietic Stem Cell Transplantation (HSCT), commonly known as Bone Marrow Transplantation (BMT), is a life-saving procedure used to reconstitute a patient's haematopoietic system following high-dose chemotherapy or radiation, with allogeneic HSCT achieving long-term disease-free survival rates of 50–80% depending on disease type, donor compatibility, and patient fitness.

30–60 days (inpatient; varies by transplant type — autologous typically 21–35 days, allogeneic 40–60 days)
Hospital Stay
10–16 weeks from transplant day (fit-to-fly clearance requires stable engraftment, absence of active GVHD, ANC ≥ 0.5 × 10⁹/L sustained, and infectious disease clearance by the treating haematologist)
Total Stay in Country (Fit-to-Fly)
50–80% long-term disease-free survival (disease- and donor-dependent; autologous HSCT for multiple myeloma: 70–85%; matched sibling allogeneic HSCT for AML in CR1: 55–70%)
Success Rate

Clinical Overview

  • Haematopoietic Stem Cell Transplantation (HSCT) is the infusion of pluripotent haematopoietic progenitor cells — sourced from bone marrow, peripheral blood, or umbilical cord blood — into a conditioned recipient with the goal of restoring normal haematopoiesis and, in allogeneic settings, inducing a graft-versus-tumour (GVT) immune effect.
  • The procedure is broadly classified as autologous (patient's own stem cells re-infused after myeloablative chemotherapy) or allogeneic (donor cells from a matched sibling, matched unrelated donor, haploidentical relative, or cord blood unit).
  • The physiological impact is profound: conditioning regimens such as BuCy (busulfan + cyclophosphamide), FluBu (fludarabine + busulfan), or TBI-based protocols ablate the recipient's marrow, rendering them profoundly immunosuppressed and pancytopenic for 2–6 weeks before donor engraftment restores marrow function.
Full details →

Who is a Candidate?

  • ELIGIBLE CONDITIONS (Malignant): Acute Myeloid Leukaemia (AML) in CR1/CR2, Acute Lymphoblastic Leukaemia (ALL) in CR1 (high-risk) or CR2, Chronic Myeloid Leukaemia (CML) in accelerated/blast phase or TKI-refractory, Myelodysplastic Syndromes (MDS) with IPSS-R intermediate or higher, Hodgkin and Non-Hodgkin Lymphoma (relapsed/refractory or high-risk), Multiple Myeloma (autologous HSCT as consolidation post-induction), Myelofibrosis (allogeneic HSCT for DIPSS+ intermediate-2 or high risk)
  • ELIGIBLE CONDITIONS (Non-Malignant): Severe Aplastic Anaemia (SAA), Thalassaemia Major (Lucarelli Class I–III), Sickle Cell Disease with major organ complications, SCID and primary immunodeficiencies, Fanconi Anaemia, Wiskott-Aldrich Syndrome, Hurler Syndrome and selected lysosomal storage disorders, POEMS syndrome
  • ELIGIBLE CONDITIONS (Autoimmune — Investigational/Specialist Centres): Refractory Multiple Sclerosis (MS), Systemic Sclerosis, Crohn's Disease (autologous HSCT under EBMT guidelines)
  • REQUIRED PRE-TRANSPLANT DIAGNOSTICS: Bone marrow biopsy and trephine with cytogenetics (karyotype, FISH), molecular profiling (NGS panel for FLT3, NPM1, IDH1/2, TP53, ASXL1), HLA typing (high-resolution 10/10 allele-level for patient and donor), PET-CT scan (for lymphoma patients to confirm complete remission pre-transplant), ECHO (left ventricular ejection fraction must typically be ≥ 45%), Pulmonary Function Tests (DLCO ≥ 50% predicted), Creatinine clearance (GFR ≥ 40–60 mL/min depending on regimen), Liver function and bilirubin (Child-Pugh scoring), CMV/EBV/HSV/VZV/HBV/HCV/HIV serology for patient and donor, HCT-CI comorbidity scoring, Dental clearance and ENT evaluation, Fertility counselling and sperm/oocyte cryopreservation discussion
  • +1 more

Treatment Options & Approaches

  • AUTOLOGOUS HSCT (Auto-SCT):

Recovery

  • PHASE 1 — INITIAL ASSESSMENT & GAF HEALTHCARE CASE REVIEW (Weeks -12 to -8 before transplant):

Risks to be aware of

  • HSCT carries significant treatment-related morbidity and mortality that every patient and family must understand prior to proceeding.
  • The overall treatment-related mortality (TRM) at 100 days ranges from 2–5% for autologous HSCT in fit patients to 10–25% for myeloablative allogeneic HSCT in high-risk or older patients, largely driven by infection, organ toxicity, and GVHD.
Full details →

Why GAF Healthcare

  • GAF Healthcare provides comprehensive end-to-end non-medical support for international HSCT patients and their attendants, ensuring that logistical complexity never becomes a barrier to accessing life-saving treatment.

Cost Range for Related Procedures

Bone Marrow Transplant (BMT)$18,000–$35,000
Get a personalised estimate with our cost calculator →

Common questions about Hematopoietic Stem Cell Transplantation (HSCT)

What is the cost of Haematopoietic Stem Cell Transplantation (HSCT) / Bone Marrow Transplantation in India versus the UAE?
The total in-hospital cost of HSCT varies significantly based on the transplant type (autologous vs. allogeneic), donor source (matched sibling, matched unrelated, or haploidentical), conditioning regimen intensity, length of inpatient stay, and any complications requiring additional intervention. In India, autologous HSCT (e.g., for multiple myeloma or lymphoma) typically costs between USD 18,000 and USD 28,000 inclusive of conditioning chemotherapy, stem cell collection and cryopreservation, the transplant admission (21–35 days), supportive medications, blood products, and standard monitoring. Allogeneic HSCT — matched sibling, MUD, or haploidentical — costs between USD 28,000 and USD 45,000, with higher costs driven by longer inpatient stays (40–60 days), GVHD prophylaxis drugs (tacrolimus, sirolimus, ATG), and intensive infection surveillance. These costs reflect care at NABH- and JCI-accredited centres in cities such as Mumbai, Delhi, Bengaluru, Chennai, and Hyderabad, which collectively perform among the highest volumes of HSCT in Asia. In the UAE (Dubai and Abu Dhabi), the same procedures are priced at USD 45,000–65,000 for autologous HSCT and USD 70,000–110,000 for allogeneic HSCT. UAE centres offer premium single-room accommodation, internationally trained nursing staff with lower nurse-to-patient ratios, and luxury patient services, along with JCI accreditation and DHA/DOH regulatory oversight. These costs are still 60–75% below equivalent procedures in the United States (where allo-HSCT routinely exceeds USD 300,000–500,000) or the United Kingdom. Neither range includes international matched unrelated donor (MUD) search and procurement fees (typically USD 5,000–20,000 depending on the registry and urgency), pre-transplant diagnostics conducted abroad, post-discharge outpatient medications, or return flights and accommodation. GAF Healthcare provides a fully itemised, personalised cost estimate within 5–7 business days of receiving complete medical records.
How long do I need to stay in India or the UAE before I am fit to fly home after HSCT?
HSCT requires one of the longest mandatory in-country stays of any medical procedure, and patients and families must plan accordingly. The minimum in-country duration before fit-to-fly clearance is 10–16 weeks from the day of stem cell infusion (Day 0), though the median for allogeneic HSCT patients is 12–14 weeks. The hospital inpatient admission itself lasts 21–35 days for autologous HSCT and 40–60 days for allogeneic HSCT (longer if complications such as GVHD, CMV reactivation, or prolonged engraftment occur). Following discharge from the inpatient unit, patients are not fit to fly and must remain near the transplant centre for outpatient monitoring. During this phase, patients are seen 3–5 times per week (reducing to weekly as recovery progresses) for blood counts, drug level monitoring, GVHD assessment, and infectious surveillance. Formal fit-to-fly clearance is issued by the transplant physician when ALL of the following criteria are met: - Absolute Neutrophil Count (ANC) sustainably above 1.0 × 10⁹/L without G-CSF support - Platelet count ≥ 50 × 10⁹/L (or ≥ 80 × 10⁹/L for long-haul flights > 8 hours, at many centres) - No active GVHD Grade II or above requiring escalation of therapy - No active systemic infection (bacterial, fungal, or viral) - Stable oral immunosuppression with documented therapeutic drug levels - ECOG Performance Status ≤ 2 (patient can perform basic self-care and ambulate) - No supplemental oxygen requirement For allogeneic HSCT patients, fit-to-fly is rarely achievable before Week 10 post-transplant, and the majority are cleared between Weeks 12 and 16. Autologous HSCT patients may occasionally achieve fit-to-fly clearance as early as Week 6–8, but Week 8–12 is more typical. These timelines can be extended by complications. GAF Healthcare's Case Manager works with the transplant team to coordinate fit-to-fly certification, arrange medical escort if required, and liaise with airlines regarding oxygen requirements, preboarding, and infection precautions during travel.
What is the success rate of HSCT / Bone Marrow Transplantation?
The success rate of HSCT is not a single number — it is disease-specific, risk-stratified, and dependent on multiple patient, disease, and transplant-related factors. Published outcomes from EBMT (European Bone Marrow Transplantation Registry), CIBMTR (Center for International Blood and Marrow Transplant Research), and individual high-volume centres provide the most reliable benchmark data. KEY OUTCOME BENCHMARKS BY DISEASE AND TRANSPLANT TYPE: - Autologous HSCT for Multiple Myeloma (MM): 5-year progression-free survival (PFS) of 40–55% with modern induction (VRd or Dara-VRd) plus autologous transplant and lenalidomide maintenance; overall survival (OS) exceeds 70–80% at 5 years with tandem auto approach in high-risk disease. - Autologous HSCT for Hodgkin Lymphoma (relapsed/refractory, chemosensitive): 5-year OS of 50–60%; when combined with brentuximab vedotin consolidation post-transplant, 5-year PFS improves to approximately 65%. - Allogeneic HSCT for AML in First Complete Remission (CR1), standard-risk: 5-year disease-free survival (DFS) of 55–70% with matched sibling donor; 50–65% with MUD; approximately 45–60% with haploidentical (PTCy protocol). - Allogeneic HSCT for ALL in CR1 (high-risk, Ph+ or MRD-positive): 5-year DFS of 50–65% with MSD; outcomes are strongly influenced by MRD negativity at transplant. - Allogeneic HSCT for Severe Aplastic Anaemia (SAA) with MSD in patients < 40 years: 5-year OS exceeding 85–90%, making it potentially curative in the majority. - Allogeneic HSCT for Thalassaemia Major (Lucarelli Class I): event-free survival (EFS) of 85–93% in paediatric patients with MSD and good pre-transplant hepatic status. - Allogeneic HSCT for MDS (IPSS-R High/Very High): 3-year OS of 35–50%, heavily dependent on cytogenetic risk and MRD status at transplant. CRITICAL PROGNOSTIC FACTORS: The Disease Risk Index (DRI) — low, intermediate, high, and very high — is the most validated risk stratification tool and correlates strongly with post-HSCT survival. Low-DRI patients achieve 3-year OS > 65%; very-high-DRI patients < 30%. The HCT-CI (Haematopoietic Cell Transplantation Comorbidity Index) predicts treatment-related mortality independent of disease. KPS/ECOG performance status, CMV serostatus, MRD negativity at transplant, and donor-recipient sex mismatch also independently influence outcomes. GAF Healthcare's partner centres in India and the UAE report outcomes that are broadly consistent with published EBMT and CIBMTR registry data, reflecting their volume, experience, and protocol adherence. During the case review process, GAF Healthcare will share the transplant centre's disease-specific outcome data and help patients and families interpret the individualised risk-benefit assessment provided by the treating haematologist.

Related pages

How GAF Healthcare Assists in Choosing the Best Hospital for Hematopoietic Stem Cell Transplantation (HSCT) in Chennai, India

Discover the Top Hospitals for Hematopoietic Stem Cell Transplantation (HSCT) in Chennai, India

This page lists 8 accredited bone marrow transplant hospitals in Chennai, India, so you can compare accreditation, specialties and bed capacity in one place.

Support When You Need It Most

Share your medical reports with us on WhatsApp or email. Our medical team reviews them and comes back with a recommended hospital and treatment plan for your case.

Transparent, All-Inclusive Costs

We provide a single, itemised quote covering hospital charges and stay — no hidden fees, and there's no charge for requesting an estimate. Use our cost calculator alongside this page for a first estimate.

Visa, Travel and Stay Coordination

Once you choose a hospital, we help arrange the medical visa invitation letter, hotel or serviced-apartment booking nearby, airport pickup and transport to your appointments.

Curious what treatment might cost for your case? Use our cost calculator for a personalized estimate.

Common Questions

Frequently asked questions about hematopoietic stem cell transplantation (hsct) in Chennai, India

How many bone marrow transplant hospitals are listed in Chennai, India?
8 hospitals in our Chennai, India directory are currently listed for bone marrow transplant including Hematopoietic Stem Cell Transplantation (HSCT).
How do you choose which hospitals to list?
A hospital appears on this page when Bone Marrow Transplant is among its listed specialties and it is located in Chennai, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
How much does treatment cost in India?
Cost varies by hospital, city and individual case. Use our cost calculator for a personalized estimate — see the link on this page.
Are there bone marrow transplant hospitals for this in other India cities?
See the "Hospitals in other cities" links on this page for the full India list.
Are these hospitals internationally accredited?
Hospitals listed on this page carry accreditations including JCI, NABH, NABL — see the accreditation badge shown for each hospital below.
Can I get a treatment plan and cost estimate before I travel?
Yes. Share your medical reports with the GAF Healthcare team over WhatsApp or email, and our medical team will review them and come back with a recommended hospital, a treatment plan and an itemised cost estimate before you commit to anything.
Do you help with visa, travel and accommodation?
Yes. Once you choose a hospital, our team helps arrange the medical visa invitation letter, book accommodation near the hospital, and organise airport pickup and transport to appointments.
What support do I get during and after treatment?
Our medical team reviews your reports and stays in touch throughout your treatment journey — from the first consultation through recovery, including after you return home.
What does the "Featured" label next to a hospital's name mean?
"Featured" reflects editorial prominence on this listing, not a clinical ranking or a claim that it is the "best" hospital.
How do I get matched with the right hospital for hematopoietic stem cell transplantation (hsct)?
Share your medical reports and requirements with the GAF Healthcare team, and our medical coordinators will recommend a suitable hospital from this list based on your case.
Does the listed cost cover everything?
The figures shown are an indicative planning estimate, not a final quote from a specific hospital. Our team provides a single, itemised, all-inclusive quote before you make any commitment.
🤔

Still have questions?

Our coordinators are here to answer your questions about hematopoietic stem cell transplantation (hsct) in Chennai, India.

Next Step

Share your medical reports with us and our team will recommend a hospital and treatment plan for hematopoietic stem cell transplantation (hsct) in Chennai, India.

Contact us to report an inaccuracy on this page.

WhatsApp Us